http://www.cockatoocoal.com.au/tasks/sites/cok/assets/File/100603_COK_-_MF_Research.pdf?doaction=returnAnd this also by Andrew Gardner. These are a bit dated but give you the general theme of a vastly underpriced company.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%